StephenLiuMD(He/Him)
Oncology • Washington, DCThoracic Cancer
Associate Professor, Georgetown University School of Medicine
Dr. Liu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3800 Reservoir Rd NW
Lombardi Comprehensive Cancer Clinic
Washington, DC 20007Phone+1 202-444-2223Fax+1 202-444-7009
Summary
- Dr. Stephen V. Liu, MD, is an Associate Professor of Medicine, Director of Thoracic Oncology and Head of Developmental Therapeutics at the Lombardi Comprehensive Cancer Center of Georgetown University in Washington DC, USA. He is also the host for the official IASLC podcast, Lung Cancer Considered.
Education & Training
University of Southern California/LAC+USC Medical CenterFellowship, Hematology, 2009 - 2010- University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 2008 - 2009
University of Pennsylvania Health SystemResidency, Internal Medicine, 2005 - 2008
University of Maryland School of MedicineClass of 2005
Certifications & Licensure
CA State Medical License 2008 - Present
MD State Medical License 2013 - 2026
DC State Medical License 2013 - 2024
PA State Medical License 2005 - 2008- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2013
Clinical Trials
- Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor Start of enrollment: 2016 May 11
- A Study of EP0031 in Patients With Advanced RET-altered Malignancies Start of enrollment: 2022 Sep 30
Roles: Contact
- A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) Start of enrollment: 2022 Jan 04
Publications & Presentations
PubMed
- 201 citationsPralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.Justin F. Gainor, Giuseppe Curigliano, Dong Wan Kim, Dae Ho Lee, Benjamin Besse
The Lancet. Oncology. 2021-07-01 - 1910 citationsFirst-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung CancerLeora Horn, Aaron S. Mansfield, Aleksandra Szczesna, Libor Havel, Maciej Krzakowski
The New England Journal of Medicine. 2018-09-25 - 31 citationsAddressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer.Sanjay Popat, Stephen V Liu, Nicolas Scheuer, Grace G Hsu, Alexandre Lockhart
Nature Communications. 2022-06-17
Press Mentions
After "Astounding" Survival Results in SCLC, Updated Data Raise QuestionSeptember 17th, 2024- Second-Line Treatment Shortfall for Metastatic NSCLCJune 7th, 2024
- Immunotherapy, Next-Generation Sequencing, and Shared Decision-Making in the Treatment of Non–Small Cell Lung CancerMay 17th, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
